and phlebitis or thrombophlebitis, I801-I809; increased substantially (online Appendix Figure, available from www.cdc.gov/EID/content/13/ 10/1510-appG.htm). Increases occurred in specifi c primary diagnoses from 1997-1998 to 2003-2004 ; the largest percentage increase was for phlebitis or thrombophlebitis of the femoral vein, I801, from 60 to 533 (788%). Increases were also observed for aneurysm or pseudoaneurysm of an artery of a lower limb, I724, from 9 to 62 (589%), cutaneous abscess of trunk or groin, L022, from 92 to 613 (566%), cellulitis of trunk or groin, L033, from 13 to 74 (469%), and, phlebitis or thrombophlebitis of deep vessels of the lower limb other than the femoral vein, I802, from 269 to 1,314 (388%).
No national data exist for the prevalence of injection drug use in England (7) . Although the number of opiate injecting drug users may have increased in the 1990s (8) , the rapid and substantial increase in admissions for SSTIs and vascular disease suggests that this has not resulted from an increase in the injecting population alone.
The contribution to the increase in admissions from subcutaneous or muscle injecting and intravenous injecting cannot be determined from these data. The increases for phlebitis or thrombophlebitis of the femoral vein and aneurysm or pseudoaneurysm of the lower limb suggest that groin injecting may have contributed to the study fi ndings (9) . The choice of drugs may have contributed to our fi ndings. An association between injecting site infections in England has been reported with crack cocaine injection and elsewhere with cocaine injection (2, 3, 7) .
This study has some limitations. The HES database does not distinguish between injection and noninjection drug users and whether injection was intravenous or subcutaneous and intramuscular. The study does not relate HES data entries to the conditions described directly by the physical examination of patients or the review of clinical notes. Those conditions associated with femoral vein injection do not exclusively result from this practice, and the proportion of these admissions not associated with injection drug use is unknown. The study period was limited by date of the introduction of ICD-10 coding; therefore, earlier trends could not be identifi ed. Nevertheless, this analysis highlights a potentially important trend and the need for further quantitative and qualitative research in injection drug users.
The response to these problems could be addressed by changing behavior and improving access to healthcare (1). Ideally, injection drug users (IDUs) should have early entry to, and be retained on, substance abuse treatment, particularly methadone maintenance (1). Skin and muscle injecting, and injecting into the femoral vein should be discouraged (3). To inject safely, IDUs need access to clean equipment to prevent the use of shared and dirty needles and the reuse of syringes. Injection sites should be rotated, the skin should be cleaned with alcohol, and the licking of needles and booting should be discouraged (1-3). Patients were predominantly admitted through emergency departments, which suggests poor contact with health services and reluctance to seek treatment until the point of crisis (10) . Early medical treatment is required, possibly with the creation of hospitalbased SSTI clinics, as were successfully introduced in San Francisco, or improved community outreach (1) .
In summary, this study identifi es a rapid and important increase in the hospitalization of drug users in England for SSTIs and vascular conditions. Further work is required to obtain more information about these clinical problems and the patients' associated lifestyle, on admission and in the community. Means of discouraging risk-related behavior and treatment should be implemented before the conditions require urgent hospital admission. HES 
